Evaluation of the impact of the exposure route on the human kinetic adjustment factor

Regulatory Toxicology and Pharmacology

Volumn 59, Issue 2, 2011, Pages 258-269

  Valcke, M ^a,b   Krishnan, K ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

Chemical specific adjustment factors (CSAF); Drinking water contaminants; Exposure route; Human kinetic adjustment factor (HKAF); Physiologically based pharmacokinetic (PBPK) modelling; VOCs

Indexed keywords

BROMOFORM; CHLOROFORM; CYTOCHROME P450 2E1; DRINKING WATER; TETRACHLOROETHYLENE; TRICHLOROETHYLENE;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CONTROLLED STUDY; DENSITY FUNCTIONAL THEORY; ENVIRONMENTAL EXPOSURE; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; HUMAN IMPACT (ENVIRONMENT); LIVER METABOLISM; LONG TERM EXPOSURE; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MONTE CARLO METHOD; NEWBORN; PRIORITY JOURNAL; RISK ASSESSMENT; STOCHASTIC MODEL; TOXICOKINETICS; WATER CONTAMINATION;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CHLOROFORM; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2E1; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INHALATION EXPOSURE; MIDDLE AGED; MODELS, BIOLOGICAL; PHARMACOKINETICS; PREGNANCY; RISK ASSESSMENT; TRIHALOMETHANES; VINYL CHLORIDE; WATER POLLUTANTS, CHEMICAL;

EID: 79952073198     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.10.008     Document Type: Article

References (69)

1. ATSDR, 1997a. Toxicological Profile for Chloroform. Agency for Toxic Substances and Disease Registry.
2. ATSDR, 1997b. Toxicological Profile for Tetrachloroethylene. Agency for Toxic Substances and Disease Registry.
3. ATSDR, 1997c. Toxicological Profile for Trichloroethylene. Agency for Toxic Substances and Disease Registry.
4. ATSDR, 2005. Toxicological Profile for Bromoform and Dibromochloromethane. Agency for Toxic Substances and Disease Registry.
5. Bois F.Y., Zeise L., Tozer T.N. Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats, and humans. Toxicol. Appl. Pharmacol. 1990, 102:300-315.
6. Brochu P., Ducré-Robitaille J.F., Brodeur J. Physiological daily inhalation rates for free-living pregnant and lactating adolescents and women aged 11-55years, using data from doubly labelled water measurements for use in health risk assessment. Hum. Ecol. Risk Assess. 2006, 12:702-735.
7. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13:407-484.
8. CalEPA Public Health Goal for Chemicals in Drinking Water - Trichloroethylene. Pesticide and Environmental Toxicology Branch. Office of Environmental Health Hazard Assessment 2009, California Environmental Protection Agency, Sacramento, CA.
9. Clewell H.J., Gearhart J.M., Gentry P.R., Covington T.R., VanLandingham C.B., Crump K.S., Shipp A.M. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal. 1999, 19:547-558.
10. Clewell H.J., Gentry P.R., Covington T.R., Gearhart J.M. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ. Health Perspect. 2000, 108(Suppl. 2):283-305.
11. Clewell H.J., Gentry P.R., Covington T.R., Sarangapani R., Teeguarden J.G. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 2004, 79:381-393.
12. Clewell H.J., Gentry P.R., Kester J.E., Andersen M.E. Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene. Crit. Rev. Toxicol. 2005, 35:413-433.
13. Clewell H.J., Lee T.S., Carpenter R.L. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal. 1994, 14:521-531.
14. Clewell H.J., Teeguarden J., McDonald T., Sarangapani R., Lawrence G., Covington T., Gentry R., Shipp A. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 2002, 32:329-389.
15. Corley R.A., Mendrala A.L., Smith F.A., Staats D.A., Gargas M.L., Conolly R.B., Andersen M.E., Reitz R.H. Development of a physiologically based pharmacokinetic model for chloroform. Toxicol. Appl. Pharmacol. 1990, 103:512-527.
16. DeWoskin R.S., Thompson C.M. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul. Toxicol. Pharmacol. 2008, 51:66-86.
17. Dorne J.L., Walton K., Renwick A.G. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem. Toxicol. 2005, 43:203-216.
18. Dorne J.L., Renwick A.G. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol. Sci. 2005, 86:20-26.
19. Dourson M.L., Felter S.P., Robinson D. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 1996, 24(2 Pt. 1):108-120.
20. Dourson M.L., Stara J.F. Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 1983, 3:224-238.
21. Faustman E.M., Ribeiro P. Pharmacokinetic consideration in developmental toxicity. Developmental Toxicology: Risk Assessment and the Future 1990, 109-136. Van Nostrand Reinhold, New York. R.D. Hood (Ed.).
22. Fernandez J., Guberan E., Caperos J. Experimental human exposures to tetrachloroethylene vapor and elimination in breath after inhalation. Am. Ind. Hyg. Assoc. J. 1976, 37:143-150.
23. Gargas M.L., Burgess R.J., Voisard D.E., Cason G.H., Andersen M.E. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol. 1989, 98:87-99.
24. Gearhart J.M., Mahle D.A., Greene R.J., Seckel C.S., Flemming C.D., Fisher J.W., Clewell H.J. Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE). Toxicol. Lett. 1993, 68(1-2):131-144.
25. Gentry P.R., Hack C.E., Haber L., Maier A., Clewell H.J. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol. Sci. 2002, 70:120-139.
26. Ginsberg G., Hattis D., Sonawane B., Russ A., Banati P., Kozlak M., Smolenski S., Goble R. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 2002, 66:185-200.
27. Haddad S., Pelekis M., Krishnan K. A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. Toxicol. Lett. 1996, 85:113-126.
28. Haddad S., Restieri C., Krishnan K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J. Toxicol. Environ. Health A 2001, 64:453-464.
29. Haddad S., Tardif G.C., Tardif R. Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes. J. Toxicol. Environ. Health A 2006, 69:2095-2136.
30. Health Canada, 2005. Guidelines for Canadian Drinking Water Quality: Supporting Documentations - Trichloroethylene. Water Quality and Health Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, ON.
31. Health Canada, 2006. Guidelines for Canadian Drinking Water Quality: Supporting Documentations - Trihalomethanes. Water Quality and Health Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, ON.
32. ICRP Publication 89. Ann. ICRP 2002, 32(3-4):5-265. ICRP.
33. IPCS, 1994. Assessing human health risks of chemicals: derivation of guidance values for health based exposure limits. Environmental Health Criteria, vol. 170. International Panel on Chemical Safety, World Health Organization, Geneva, Switzerland .
34. IPCS, 2005. Chemical-Specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability: Guidance Document for the Use of Data in Dose/Concentration-Response Assessment. WHO/IPCS/01.4, 1-96. International Panel on Chemical Safety, World Health Organization, Geneva, Switzerland.
35. Johnsrud E.K., Koukouritaki S.B., Divakaran K., Brunengraber L.L., Hines R.N., McCarver D.G. Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther. 2003, 307:402-407.
36. Kirman C.R., Gargas M.L., Marsh G.M., Strother D.E., Klaunig J.E., Collins J.J., Deskin R. Cancer dose-response assessment for acrylonitrile based upon rodent brain tumor incidence. use of epidemiological, mechanistic, and pharmacokinetic support of nonlinearity. Regul. Toxicol. Pharmacol. 2005, 43:85-103.
37. Kirman C.R., Sweeney L.M., Gargas M.L., Strother D.E., Collins J.J., Deskin R. Derivation of noncancer reference values for acrylonitrile. Risk Anal. 2008, 28:1375-1393.
38. Klingler M., Demmelmair H., Larque E., Koletzko B. Analysis of FA contents in individual lipid fractions from human placental tissue. Lipids 2003, 38:561-566.
39. Lévesque B., Ayotte P., Tardif R., Ferron L., Gingras S., Schlouch E., Gingras G., Levallois P., Dewailly E. Cancer risk associated with household exposure to chloroform. J. Toxicol. Environ. Health A 2002, 65:489-502.
40. Lindstrom A.B., Highsmith V.R., Buckley T.J., Pate W.J., Michael L.C. Gasoline-contaminated ground water as a source of residential benzene exposure: a case study. J. Expo. Anal. Environ. Epidemiol. 1994, 4:183-195.
41. Lipscomb J.C., Teuschler L.K., Swartout J., Swan G.E., Snawder J.E. Variance of microsomal protein and cytochrome P450 2E1 and 3A forms in adult human liver. Toxicol. Mech. Meth. 2003, 13:45-51.
42. McKone T.E. Human exposure to volatile organic compounds in household tapwater: the indoor inhalation pathway. Environ. Sci. Technol. 1987, 21:1194-1201.
43. Meek M.E., Renwick A., Ohanian E., Dourson M., Lake B., Naumann B.D., Vu V. Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. Toxicology 2002, 181-182:115-120.
44. Mörk A.K., Johanson G. Chemical-specific adjustment factors for intraspecies variability of acetone toxicokinetics using a probabilistic approach. Toxicol. Sci. 2010, 116:336-348.
45. Muller G., Spassovski M., Henschler D. Metabolism of trichloroethylene in man. III. Interaction of trichloroethylene and ethanol. Arch. Toxicol. 1975, 33:173-189.
46. Nelson, W.E., 1991. Textbook of Pediatrics. W.B. Sauders Company.
47. Nong A., Krishnan K. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach. Regul. Toxicol. Pharmacol. 2007, 48:93-101.
48. Nong A., McCarver D.G., Hines R.N., Krishnan K. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol. 2006, 214:78-87.
49. Pelekis M., Nicolich M.J., Gauthier J.S. Probabilistic framework for the estimation of the adult and child toxicokinetic intraspecies uncertainty factors. Risk Anal. 2003, 23:1239-1255.
50. Poulin P., Krishnan K. A biologically-based algorithm for predicting human tissue: blood partition coefficients of organic chemicals. Hum. Exp. Toxicol. 1995, 14:273-280.
51. Poulin P., Krishnan K. A mechanistic algorithm for predicting blood:air partition coefficients of organic chemicals with the consideration of reversible binding in hemoglobin. Toxicol. Appl. Pharmacol. 1996, 136:131-137.
52. Price K., Haddad S., Krishnan K. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health A 2003, 66:417-433.
53. Price P.S., Conolly R.B., Chaisson C.F., Gross E.A., Young J.S., Mathis E.T., Tedder D.R. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 2003, 33:469-503.
54. Rao H.V., Brown D.R. A physiologically-based pharmacokinetic model assessment of tetrachloroethylene in groundwater for a bathing and showering determination. Risk Anal. 1993, 17:583-598.
55. Sarangapani R., Gentry P.R., Covington T.R., Teeguarden J.G., Clewell H.J. Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal. Toxicol. 2003, 15:987-1016.
56. Soucek B., Vlachova D. Excretion of trichloroethylene metabolites in human urine. Br. J. Ind. Med. 1960, 17:60-64.
57. Statistics Canada, 2003. Canadian Community Health Survey, Cycle 2.1. (last accessed 01.02.2010). http://www.statcan.gc.ca/cgi-bin/imdb/p2SV.pl?Function=getSurvey&SurvId=3226&SurvVer=0&SDDS=3226&InstaId=15282&InstaVer=2&lang=en&db=imdb&adm=8&dis=2.
58. Sweeney L.M., Gargas M.L., Strother D.E., Kedderis G.L. Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Toxicol. Sci. 2003, 71:27-40.
59. Tan Y.M., Liao K.H., Clewell H.J. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J. Expo. Sci. Environ. Epidemiol. 2007, 17:591-603.
60. Taniguchi H., Oguro A., Koyama H., Masuyama M., Takahashi T. Analysis of models for quantification of arterial and portal blood flow in the human liver using PET. J. Comput. Assist. Tomogr. 1996, 20:135-144.
61. Tardif R., Droz P.O., Charest-Tardif G., Pierrehumbert G., Truchon G. Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. Toxicol. Lett. 2002, 134(1-3):155-163.
62. Thomas R.S., Bigelow P.L., Keefe T.J., Yang R.S. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. Am. Ind. Hyg. Assoc. J. 1996, 57:23-32.
63. US EPA, 2002. A Review of the Reference Dose and Reference Concentration Process. Risk Assessment Forum. EPA/630/P-02/00F. US EPA, Washington, DC.
64. US EPA, 2004. Estimated Per Capita Water Ingestion and Body Weight in the United States - An Update. Office of Science and Technology, Office of Water. EPA-822-R-00-001. US Environmental Protection Agency, Washington, DC 20460.
65. US EPA, 2010. Integrated Risk Information System. (last accessed 01.02.2010). http://www.cfpub.epa.gov/ncea/iris/index.cfm?fuseaction=iris.showSubstanceList.
66. Valcke M., Krishnan K. Physiologically based pharmacokinetic modeling in the risk assessment of developmental toxicants. Developmental Toxicology 2009, 243-274. Informa Health Care, New York. D.K. Hansen, B.D. Abbott (Eds.).
67. Verner M.A., Ayotte P., Muckle G., Charbonneau M., Haddad S. A physiologically based pharmacokinetic model for the assessment of infant exposure to persistent organic pollutants in epidemiologic studies. Environ. Health Perspect. 2009, 117:481-487.
68. Volkel W., Friedewald M., Lederer E., Pahler A., Parker J., Dekant W. Biotransformation of perchloroethene: dose-dependent excretion of trichloroacetic acid, dichloroacetic acid, and N-acetyl-S-(trichlorovinyl)-l-cysteine in rats and humans after inhalation. Toxicol. Appl. Pharmacol. 1998, 153:20-27.
69. Wang Y., Moss J., Thisted R. Predictors of body surface area. J. Clin. Anesth. 1992, 4:4-10.